Two recent studies of lenvatinib, a kinase inhibitor acting on the VEGFR, PDGFR, FGFR, KIT, and RET pathways, have shown exciting results in reducing tumor burden in patients with recurrent/metastatic ACC [22,23]. This evidence concerns the gene PDGFRB and adrenal cortex carcinoma.